A total of seven CD274/PD-L1 CN gains (0.4%, 7/1918) and five PD-L1 CN deletions (0.3%, 5/1918) were identified, and only one sample originated from primary breast cancer with the HER2 subtype and the other samples were from metastatic sites. This evidence concerns the gene ERBB2 and breast carcinoma.